Many agents are known to cause qualitative and quantitative differences in intrarenal blood flow. This study tested the hypothesis that angiotensin II (AII) evokes a differential effect on cortical (CBF) and medullary blood flow (MBF) and that AT 2 receptor mediates AII-induced increase in renal MBF by mechanisms related to nitric oxide (NO) and prostanoids. AII (100, 300 and 1000 µg/kg/min) increased mean arterial blood pressure (MABP) by 24% ± 7% (p < 0.05); decreased CBF by 30% ± 2% (p < 0.05); but increased MBF by 21% ± 8% (p < 0.05). Indomethacin (5 mg/kg), enhanced AII effects on MABP by 154% ± 26% (p < 0.05), MBF by 141% ± 46% but decreased CBF by 74% ± 54% (p < 0.05) indicating the involvement of dilator prostanoids in the systemic and medullary circulation but constrictor prostanoids in the cortex. N G nitro-L-arginine (L-NNA), an inhibitor of NO synthase (100 mg/L in drinking water) enhanced AII effects on MABP (169 ± 75, p < 0.05) and decreased CBF (107% ± 50%, p < 0.05) but blunted the effects of AII on MBF (150% ± 21%, p < 0.05). 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ; 2 mg/kg), a guanylyl cyclase inhibitor, enhanced AII effects on MABP (118% ± 32% , p < 0.05) and decreased CBF(85% ± 47% , p < 0.05) but blunted the effects of AII on MBF (96% ± 15%, p < 0.05). However, glibenclamide (20 µg/kg), a K ATP channel blocker, did not affect intra-renal hemodynamics elicited by AII. Blockade of AT 2 receptors with PD123319 (50 µg/kg/min) did not change basal or AII-induced changes MABP or CBF but blunted AII-induced increase in MBF by 60% ± 11% (p < 0.05). CGP42112 (10 µg/kg/min), an AT 2 receptor agonist, elicited a reduction in MABP and increases in CBF and MBF that were abolished or attenuated by PD123319. These findings demonstrate that AII elicited differential changes in intrarenal blood flow; an AT 1 -mediated reduction in CBF but an AT 2 -mediated increase in MBF. The AT 2 receptor-mediated increase in MBF involves guanylase cyclase, NO and dilator prostanoids but not K ATP channels.
Introduction
The intrarenal vasculature can respond to neural and a variety of humoral stimuli with vasodilatation or vasoconstriction, resulting in increased or decreased perfusion of renal tissue, respectively [1] . Such responses may have more serious functional consequences within the medulla than in the cortex. This is of major physiological and pathophysiological importance as the medulla is widely viewed as having a crucial role in maintaining body fluid homeostasis and in the control of arterial pressure [2] .
The renin-angiotensin system is a coordinated hormonal cascade important to the regulation of renal sodium excretion and blood pressure. The major effector peptide, angiotensin II (AII), binds to two major receptors; AT 1 and AT 2 . While the majority of AII actions are mediated via the AT 1 receptor, evidence has accumulated that the AT 2 receptor opposes the AT 1 receptor, especially by inducing vasodilation instead of vasoconstriction and may be important in the regulation of blood pressure and renal function by counterbalancing the vasoconstrictor and antinatriuretic actions of AT 1 receptors [3] . However, the roles of AT 1 and AT 2 receptors in regulating regional kidney perfusion remain unclear. In rats and rabbits, infusions of AII reduced total renal blood flow (RBF) and cortical blood flow but have a lesser effect on medullary blood flow [4, 5] . AII can even increase MBF, especially when administered as a bolus [1, 6] . Many studies have demonstrated that the medullary vasculature was poorly sensitive to the vasoconstrictor effects of AII compared with the cortical circulation [4, 7, 8] . A study [9] has shown that AII induced a potent vasoconstriction of isolated medullary vasa recta in Sprague-Dawley rats, a response also observed in conscious rats [10] . Conversely, other studies have shown that the systemic infusion of AII increased papillary blood flow in young SpragueDawley and Wistar rats [11] by increasing local medullary synthesis of vasodilator agents such as prostaglandins, nitric oxide (NO), or kinins.
Nitric oxide (NO) synthase and/or cyclooxygenase (COX) blockade can enhance AII-induced reductions in medullary blood flow (MBF) and abolish AII-induced increases in MBF, both of which are chiefly AT 1 mediated [12] [13] [14] . However, the contributions of AT 2 receptors to these effects have received little attention, even though they are expressed in vessels that might contribute to MBF control (e.g., afferent arterioles and vasa recta). In a routine experiment to address the effects of AII in the rat, we noticed a differential effect on CBF and MBF and this led us to characterize these effects. We hypothesized that AII evokes a differential effect on intrarenal hemodynamics by an AT 1 -mediated cortical vasoconstriction but AT 2 receptor-mediated increase in renal medullary blood flow. To test this hypothesis, mean arterial blood pressure (MABP), MBF and CBF responses to graded doses of AII were determined in the presence of indomethacin, N ω -nitro-L-arginine, ODQ (1H-[1,2,4] oxadiazolo[4,3,-a]quinoxalin-1-one), or glibenclamide. In addition, we characterized the increase in MBF using CGP42112, a highly selective AT 2 agonist, and PD123319, an AT 2 antagonist.
Materials and Methods

Drugs and Chemicals
N ω -nitro-L-arginine (L-NNA;Sigma-Aldrich, St. Louis, MO) and indomethacin (Sigma-Aldrich, St. Louis, MO) were dissolved in 0.1 M NaHCO 3 , and pH was adjusted to 7.0 -7.2. Glibenclamide (Sigma-Aldrich, St. Louis, MO) and 1H- [1, 2, 4] oxadiazolo [4,3, -a]quinoxalin-1-one (ODQ; Sigma-Aldrich, St. Louis, MO) were prepared in dimethylsulfoxide (DMSO) as stock solutions of 0.1 M, from which aliquots were diluted in normal saline for intravenous administration. Angiotensin II (Sigma-Aldrich), CGP42112 (21st Century Biochemicals, USA) and PD123319 (a gift from Park Davis, USA) were dissolved in normal saline (0.9% NaCl). All agents were kept on ice during the experiments.
Female Sprague-Dawley rats (230 -290 g body wt; Harlan Sprague Dawley, Houston, TX) were maintained on standard rat food (Purina Chow; Purina, St Louis, MO) and allowed ad libitum access to water and food until the beginning of the experiments. The study protocol was approved by the Animal Care and Use Committee of Texas Southern University.
Surgical Preparation
Animals were anesthetised with thiobutabarbital (Inactin), 100 mg/kg ip (Sigma-Aldrich) and placed on a heated surgical table to maintain body temperature at 37˚C. The tail vein was cannulated with a 25-gauge butterfly needle (Vacutainer, Becton and Dickson) for infusion or administration of drugs. The trachea was isolated and a polyethylene catheter (PE-250) was placed in the trachea for spontaneous ventilation. A polyethylene catheter (PE-50) was placed in the left carotid artery to monitor the blood pressure. Mean arterial blood pressure (MABP) was measured with a pressure transducer (model BLPR2, World Precision Instruments, Sarasota, FL) to a signal manifold (Transbridge, model TBM-4, World Precision Instrument, Sarasota, FL) and recorded on a data acquisition system (model DI720, DataQ Instruments, Akron, OH). The left kidney was exposed by an abdominal incision, intrarenal blood flow was measured simultaneously by laser-Doppler (LD) flowmeter (system 5000, version 1.20, Periflux, Stockholm, Sweden) via a surface probe (model PF 407) to measure CBF or an optical fiber LD probe (model PF 402) fixed to a micromanipulator and placed in the medulla (5 mm below the kidney surface) to measure MBF. CBF and MBF were recorded as perfusion units (PU).
Experimental Protocol
After surgery and placing of probes for recording regional blood flows, a 30-to 45-min equilibration period was allowed. AII was administered by an infusion pump (Model 100, SP 100i syringe pump, WPI, USA) at graded doses of 100, 300 and 1000 ng/kg/min. These graded doses were administered cumulatively. The effects on MABP, CBF and MBF were determined in the presence of indomethacin, a COX inhibitor (10 mg/kg iv; n = 6) [15] , L-NNA, N ω -nitro-L-arginine, a NO synthase inhibitor (100 mg/L in drinking water for 2 days; n = 6) [16] , ODQ, 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one, a guanylase cyclase inhibitor (2 mg/kg iv; n = 5) [17] , glibenclamide, a K ATP channel blocker (20 µg/kg, iv) [18] ; or their respective vehicles: 0.1 M NaHCO 3 for L-NNA and indomethacin, 5% DMSO for glibenclamide and ODQ and normal saline for AII. Data obtained from rats treated with 5% DMSO and 0.1 M NaHCO 3 were not different from those obtained from rats treated with normal saline; hence, data from both groups were pooled to represent control data for all the treatment groups.
Another set of experiments to characterize the possible mechanisms involved in AII-induced increase in MBF Copyright © 2012 SciRes. PP Differential Effects of Angiotensin II on Intra-Renal Hemodynamics in Rats; Contribution of Prostanoids, NO and K + Channels 390 was carried out. MABP, MBF and CBF responses to graded doses of AII were determined in the presence of CGP42114, an AT 2 receptor agonist and PD123319, an AT 2 receptor antagonist. Animals were anesthetized and the left carotid artery cannulated for MABP determination while intrarenal blood flow was measured simultaneously by a laser-Doppler (LD) flow meter. After recording baseline values, the effects of CGP42114 (10 µg/kg/min; n = 5) were evaluated on MABP, CBF and MBF at intervals of 5, 10, 15 and 20 min. After infusion was stopped, a 30 min interval was allowed for the values to return to baseline. PD123319, an AT 2 receptor antagonist was infused at 50 µg/kg/min [19] for 10 min before CGP42112 (10 µg/kg/min) was infused concurrently and the antagonistic effect of PD123319 was determined at intervals of 5, 10, 15 and 20 min. Doses of all agents used were those reported in the literature to produce significant desired effects.
Statistical Analysis
All data were expressed as mean ± SEM. Changes in systemic and renal hemodynamics were expressed as absolute values and changes from baseline. The effects of a particular agent were analysed using a two-way ANOVA followed by Tukey's multiple comparison test when appropriate. Statistical analysis was performed using Graph Pad Prism V. 4.01 where p < 0.05 was considered statistically significant.
Results
Effect of Angiotensin II Infusion on Systemic and Renal Haemodynamics
Figure 1(a) shows a representative tracing illustrating the differential effect of AII on systemic and renal haemodynamics. AII (300 and 1000 ng/kg/min) increased mean arterial blood pressure (MABP) and medullary blood flow (MBF) while decreasing renal cortical blood flow (CBF) in a dose related manner. AII (300 and 1000 ng/kg/min) increased mean arterial blood pressure (MABP) by 24 ± 5, and 47 ± 7 mmHg; decreased renal cortical blood flow (CBF) by -202 ± 69 and -98 ± 81 perfusion units (PU), but increased medullary blood flow (MBF) by 17 ± 09 and 53 ± 14 PU respectively. 42, -204 ± 83 and -96 ± 67 perfusion units (PU), respectively but increased MBF by 18 ± 10 and 52 ± 15 PU respectively. Indomethacin (10 mg/kg) enhanced AIIinduced increase in MABP by 154% ± 26% (p < 0.05), decreased CBF by 74% ± 54% (p < 0.05) and increased AII-induced increase in MBF by 141% ± 46% (p < 0.05) indicating that vasodilator prostaglandins may be contributing to the increase in MBF while the vasoconstrictor prostaglandins may be contributing to the increase in MABP or decrease in CBF elicited by AII. N G nitro-L-arginine (L-NNA; 100 mg/L in drinking water for 2 days) enhanced AII-induced increase in MABP by 169 ± 75 (p < 0.05) and decrease in CBF by 107 ± 50 (p < 0.05) but blunted the effects of AII on MBF by 150 ± 21 (p < 0.05). ODQ, a soluble guanylyl cyclase (sGC; 2 mg/kg) inhibitor, enhanced AII-induced increase in MABP by 118% ± 32% (p < 0.05) and decrease in CBF by 85% ± 47% (p < 0.05) but blunted the effects of AII on MBF by 96% ± 15% (p < 0.05). This indicates that NO and activation sGC contribute to the AII-induced increase in MBF or decrease in CBF. However, in the presence of glibenclamide there were no significant changes in AII-induced increase in MABP and MBF or decrease in CBF as compared to the control, thus indicating that ATP channels are not involved in AII-induced increase in MBF.
Effect of
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Effect of Angiotensin II Infusion on Systemic and Renal Haemodynamics as Affected by AT 2 Receptor Antagonism
The involvement of AT 2 receptors in AII-induced changes in intrarenal haemodynamics, AII (100, 300 and 1000 ng/kg/min) was infused in the presence of PD123319, an AT 2 receptor antagonist. PD123319 (50 µg/kg/min) did not change basal or AII-induced changes BP or CBF. However, PD123319 blunted AII-induced increase in MBF by 60% ± 11% (p < 0.05) (Figures 3 and 4) indicating the involvement of AT 2 receptors in AII-induced increase in MBF.
Effect of CGP42112 Alone and in Combination with PD123319 on Basal Systemic and Renal Haemodynamics
As an additional evidence to support that activation of AT 2 receptor was responsible for AII-mediated increase in MBF, the effects of CGP42112, an AT 2 receptor agonist, was tested on basal systemic and renal haemo-dynamics in the presence or absence of PD123319. Figure 5 illustrates that CGP42112 decreased basal MABP, increased basal medullary perfusion and CBF in a timedependent manner. PD123319, AT 2 receptor antagonist, attenuated CGP42112-induced decrease in MABP by 121% ± 13% (p < 0.05), and CGP42112 induced increase in CBF by 142% ± 3% (p < 0.01). CGP42112-induced increase in basal MBF was also blunted by PD123319 by 67% ± 6%. These data imply that AT 2 receptor activation accounts for the increase renal MBF by AII. (c) There is still considerable controversy regarding the relative effects of angiotensin II on CBF and MBF in anaesthetized animals perhaps reflecting a species de pendency. Thus, studies in dogs indicated that both exogenous and endogenous angiotensin II profoundly increase MBF, even at levels that have little impact on CBF [20, 22] . In contrast, in most studies in anaesthetized rats and rabbits, intravenous or renal arterial infusion of angiotensin II significantly decreased CBF but not MBF [11, 23, 24] .
Discussion
In the present study, we tested the hypothesis that AII evokes a differential effect on intrarenal hemodynamics and that the AT 2 receptor mediates the increase in the renal medullary blood flow during acute AII infusion in rats. Infusion of AII increased MABP and MBF dose dependently with associated decrease in CBF. The pressor and renal cortical vasoconstriction is a result of the vasoconstrictive effect of AII [25] probably mediated through AT 1 receptors. Several studies have shown the paradoxical increase in MBF with AII bolus dose [1, 19] . AII-induced vasodilatation, as seen in the medulla, could also have been indirect, being dependent on stimulation on the biosynthesis and/or release of vasodilator agents, such as prostaglandins, kinins or NO [26] . In order to determine which of the vasodilatory agents was involved in AII-induced increase in MBF, we examined the effect Copyright © 2012 SciRes. PP Differential Effects of Angiotensin II on Intra-Renal Hemodynamics in Rats; Contribution of Prostanoids, NO and K + Channels 394 of AII infusion in the presence of indomethacin, a COX inhibitor, L-NNA, a NO synthase inhibitor, ODQ, a sGC inhibitor or glibenclamide, a K ATP channels blocker. LNNA or ODQ enhanced AII-induced increase in MABP and decrease in CBF but remarkably inhibited AIIinduced increase in MBF. This is in agreement with the studies that showed that inhibition of NO synthesis prevented an increase in perfusion of the medulla after AII [14, 27] . NO acts through the stimulation of sGC, with subsequent formation of cyclic GMP. These findings implicate NO involvement via sGC in the increase in MBF induced by AII. These data are in agreement with previous studies [14, 27, 28] . The rate of synthesis and tissue concentration of prostaglandins is much higher in the medulla compared with the cortex, and AII stimulates prostaglandin synthesis via AT 1 receptors [28] . Prostaglandin E 2 (PGE 2 ) is a major renal cyclooxygenase metabolite of arachidonate that modulates renal hemodynamics and salt and water excretion [29] . The maintenance of normal renal blood flow and function during physiological stress is especially dependent on endogenous prostaglandin synthesis [30] buffering the vasoconstrictor effects of AII, catecholamines, and vasopressin in the kidney thereby preserving normal renal function. Contrary to previous reports showing a tonic vasodilator influence of prostaglandins on the medullary circulation [31] [32] [33] inhibition of prostaglandins by indomethacin in this study enhanced AII-induced increase in MBF. This result suggests that vasodilator prostaglandins may be contributing to the increase in MBF while the vasoconstrictor prostaglandins may be contributing to the increase in MABP or decrease in CBF elicited by AII.
K ATP channel regulation of vasoactivity in vascular beds has been documented and infusion of glibenclamide, a K ATP into rats induced mesenteric, skeletal muscle, and renal vasoconstriction [34, 35] . In vivo, K ATP channel inhibition also increases resistance to blood flow in mesentery [36] , renal cortex and medulla [32, 37] . Previous studies demonstrated that high concentrations of AII inhibit K ATP in the renal medulla [38] and infusions of K ATP channel inhibitors have been shown to decrease MBF [15, 32] . In the present studies, inhibition of K ATP channels with glibenclamide did not significantly change AII-mediated effects on systemic and renal hemodynamics.
AII acts at two main receptor subtypes: AT 1 and AT 2 receptors. AT 1 receptors are responsible for mediating most of the known actions of AII, including vasoconstriction [39] . Moreover, a role for the AT 2 receptor in opposing the actions of AT 1 receptor stimulation has been implicated in growth and cardiovascular function [39] [40] [41] . In the kidney, infusions of AII reduce total renal blood flow (RBF) and cortical perfusion measured by laser Doppler flowmetry in rats and rabbits [41] . However, medullary perfusion is relatively insensitive to the vasoconstrictor effects of AII under most experimental conditions [1, 23] . The explanation for these observations seems to be that, although AT 1 -receptor activation causes vasoconstriction within vascular elements controlling MBF, it can also cause vasodilatation by release of nitric oxide and/or prostaglandins [5] . The contributions of AT 2 receptors to the control of MBF are less clear. However, recent studies in anaesthetised rabbits suggest that AT 2 -receptor activation counteracts AT 1 -mediated vasodilatation in the renal medulla, as the AT 2 antagonist PD123319 revealed dose-dependent increases in Medullary Laser Doppler Flux (MLDF) during renal arterial infusion of AII [19] implying an AT 2 -mediated medullary vasoconstriction but AT 1 -mediated vasodilation in the rabbit. This observation is at odds with the current study and contrary to the conventional view that AT 2 receptors mediate vasodilatation [42] . In our studies, blockade of AT 2 receptors with PD123319 attenuated AII-induced increase in MBF, suggesting that the increase in MBF was AT 2 receptor mediated. These data were further confirmed by infusion of CGP41112, an AT 2 receptor agonist in the absence and presence of PD123319 to determine the effect of AT 2 receptor on basal MABP, CBF and MBF. PD123319 had no detectable effect on resting systemic or renal hemodynamics. Thus, AT 2 receptors did not appear to contribute greatly to the control of resting MBF in anesthetized rats under these experimental conditions. Activation of AT 2 receptor by CGP41112 decreased basal MABP while increasing CBF and MBF. These responses were attenuated by PD123319, confirming that AT 2 receptor is not only involved in increasing MBF but also appears to be involved in the increase in CBF and decrease in MABP. These data are at odds with studies that showed that the increased medullary perfusion was AT 1 receptor-mediated [1, 6, 19] in rats.
In conclusion, AII evoked differential effects on intrarenal haemodynamics in the rat evoking cortical vasoconstriction but medullary vasodilation. AT 2 re-ceptor appears to mediate AII-induced increase in MBF by mechanisms involving guanylase cyclase, nitric oxide and dilator prostanoids but not K ATP channels.
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